Italy Virtual Clinical Trials Market Size & Outlook
The virtual clinical trials market in Italy is expected to reach a projected revenue of US$ 329.4 million by 2030. A compound annual growth rate of 6.2% is expected of Italy virtual clinical trials market from 2024 to 2030.
The Italy virtual clinical trials market generated a revenue of USD 216.0 million in 2023 and is expected to reach USD 329.4 million by 2030.
The Italy market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
In terms of segment, interventional was the largest revenue generating study design in 2023.
Expanded Access is the most lucrative study design segment registering the fastest growth during the forecast period.
Virtual clinical trials market data book summary
Market revenue in 2023
USD 216.0 million
Market revenue in 2030
USD 329.4 million
Growth rate
6.2% (CAGR from 2024 to 2030)
Largest segment
Interventional
Fastest growing segment
Expanded Access
Historical data
2017 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Interventional, Observational, Expanded Access
Key market players worldwide
Icon PLC, PAREXEL, IQVIA Holdings Inc, Labcorp Holdings Inc, LEO Pharma, Medidata, Oracle Corp, Signant Health
Other key industry trends
In terms of revenue, Italy accounted for 2.5% of the global virtual clinical trials market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany virtual clinical trials market is projected to lead the regional market in terms of revenue in 2030.
Italy is the fastest growing regional market in Europe and is projected to reach USD 329.4 million by 2030.
Italy contributed to 9.9% of the global clinical trials market in 2020. In Italy, pharmaceutical companies often fund clinical trials acting as trial sponsors. However, investigator-initiated studies are very common in Italy.
In such cases, pharmaceutical firms may provide financial support. Italy is working for many years to become a major player in clinical studies owing to its top-level research institutions & hospitals present in the country.
As per Farmindustria, around 20% of the clinical trials in Europe are run in Italy. Italy also ranks first for the number of value-based, management entry agreements (MEAs) signed with pharmaceutical companies.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Virtual Clinical Trials Market Outlook will help companies and investors design strategic landscapes.
Interventional was the largest segment with a revenue share of 49.81% in 2023.
Horizon Databook has segmented the Italy virtual clinical trials market based on interventional, observational, expanded access covering the revenue growth of each sub-segment from 2017 to 2030.
Italy contributed to 9.9% of the global clinical trials market in 2020. In Italy, pharmaceutical companies often fund clinical trials acting as trial sponsors. However, investigator-initiated studies are very common in Italy.
In such cases, pharmaceutical firms may provide financial support. Italy is working for many years to become a major player in clinical studies owing to its top-level research institutions & hospitals present in the country.
As per Farmindustria, around 20% of the clinical trials in Europe are run in Italy. Italy also ranks first for the number of value-based, management entry agreements (MEAs) signed with pharmaceutical companies.
Italy Virtual Clinical Trials Market Study Design Outlook (Revenue, USD Million , 2018-2030)
Interventional
Observational
Expanded Access
Italy Virtual Clinical Trials Market Indication Outlook (Revenue, USD Million , 2018-2030)
Oncology
Cardiovascular
Others
Reasons to subscribe to Virtual Clinical Trials Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Virtual Clinical Trials Market Outlook databook
Our clientele includes a mix of Virtual Clinical Trials Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Virtual Clinical Trials Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Virtual Clinical Trials Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.